Evidence map›Paper›PMID 42318057›Full record

ArticleMolecular therapy. Oncology2026

Induced pluripotent stem cell-derived dendritic cells potentiate the efficacy of interleukin-12-expressing oncolytic HSV-1.

Satoru Taguchi, Hiroshi Fukuhara, Songjie Cai, Xiao-Kang Li, Akihiro Naito, Shigenori Kakutani, Yuta Takeshima, Jimpei Miyakawa, Haruki Kume, Tomoki Todo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Satoru TaguchiDepartment of Urology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
Hiroshi FukuharaDepartment of Urology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka-shi, Tokyo 181-8611, Japan.
Songjie CaiDivision of Transplantation Immunology, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan.
Xiao-Kang LiDivision of Transplantation Immunology, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan.
Akihiro NaitoDepartment of Urology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
Shigenori KakutaniDepartment of Urology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
Yuta TakeshimaDepartment of Urology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
Jimpei MiyakawaDepartment of Urology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
Haruki KumeDepartment of Urology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
Tomoki TodoDivision of Innovative Cancer Therapy, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oncolytic herpes simplex virus type 1 (HSV-1), including marketing-approved G47Δ, elicits antitumor immunity via facilitating antigen presentation during immune-mediated clearance of infected tumor cells. Dendritic cell (DC) therapy should therefore enhance oncolytic HSV-1 efficacy, but its clinical application is hindered by the need to generate autologous DCs. Induced pluripotent stem cell (iPSC) technologies offer a scalable and standardized source of DCs. Here, we investigate the therapeutic potential of combining iPSC-derived DCs (iPSDCs) with an interleukin-12-expressing oncolytic HSV-1, T-mfIL12. iPSDCs, generated from a murine embryonic fibroblast-derived iPSC line, possess characteristics and functions comparable to bone marrow-derived DCs (BMDCs), including costimulatory molecule expression, antigen uptake capacity, and the ability to stimulate CD8

Indexed as

cancer immunotherapydendritic cellG47Δherpes simplex virus type 1induced pluripotent stem cellinterleukin-12oncolytic virus therapy

Identifiers

PMID42318057
PMCPMC13273829

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.